Lilly’s Tirzepatide Effective, But Tolerability Still A Limitation

Drug Reduces A1C, Weight In Diabetes

Tirzepatide’s efficacy seems to outweigh tolerability concerns at the lower doses, but the highest dose may be relegated to niche use.

Diabetes
Tolerability could remain a limitation for Lilly's tirzepatide despite positive Phase III efficacy data • Source: Shutterstock

More from Clinical Trials

More from R&D